NCT03224117

Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat

A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Finding Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Accepted

Summary

evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat

Detailed description

DWJ211 \_ reduction of moderate or severe submental fat

Conditions

• Treatment for Submental Fat

Interventions

Type	Name	Description
DRUG	DWJ211	inject the Drug into submental fat via subcutaneous
DRUG	Normal saline	inject the Drug into submental fat via subcutaneous

Timeline

• Start date: 2017-10-26
• Primary completion: 2018-06-29
• Completion: 2018-06-29
• First posted: 2017-07-21
• Last updated: 2024-04-04

Locations

3 sites across 1 country: South Korea